Scinai Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Scinai Immunotherapeutics
SCNI Stock  USD 0.88  0.03  2.95%   
Scinai Immunotherapeuti's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Scinai Immunotherapeuti's valuation are provided below:
Gross Profit
-1.7 M
Profit Margin
4.4839
Market Capitalization
2.9 M
Enterprise Value Revenue
8.8468
Revenue
1.1 M
We have found one hundred twenty available fundamental trend indicators for Scinai Immunotherapeutics, which can be analyzed and compared to other ratios and to its competition. Traders should compare all of Scinai Immunotherapeutics current fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The Scinai Immunotherapeuti's current Market Cap is estimated to increase to about 5.8 M, while Enterprise Value is projected to decrease to under 2.4 M.

Scinai Immunotherapeuti Total Revenue

1.07 Million

Check Scinai Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scinai Immunotherapeuti's main balance sheet or income statement drivers, such as Interest Expense of 1 M, Selling General Administrative of 4.2 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 3.29, Dividend Yield of 0.0 or PTB Ratio of 0.23. Scinai financial statements analysis is a perfect complement when working with Scinai Immunotherapeuti Valuation or Volatility modules.
  
Build AI portfolio with Scinai Stock
Check out the analysis of Scinai Immunotherapeuti Correlation against competitors.

Scinai Immunotherapeuti Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12 M15.5 M15.6 M
Slightly volatile
Total Current Liabilities2.4 M2.1 M2.9 M
Slightly volatile
Accounts Payable410.8 K432.4 K1 M
Pretty Stable
Cash2.1 M2.3 M7.7 M
Pretty Stable
Long Term Debt284.1 K299 K75.3 M
Slightly volatile
Total Liabilities3.8 M4 M12.7 M
Slightly volatile
Common Stock5.3 M9.6 M7.8 M
Pretty Stable
Other Current Liabilities478.5 K898.1 K428.6 K
Slightly volatile
Other Assets571.1 K544 K235.7 K
Slightly volatile
Other Current Assets251.5 K241.5 K297.1 K
Very volatile
Intangible Assets3.2 K3.4 K24 K
Slightly volatile
Property Plant Equipment12.7 M14.6 M29.7 M
Slightly volatile
Property Plant And Equipment Net13.4 M12.7 M6.8 M
Slightly volatile
Non Current Assets Total13.4 M12.7 M7.1 M
Slightly volatile
Cash And Short Term Investments2.1 M2.3 M8.4 M
Very volatile
Net Receivables237.1 K249.6 K569 K
Pretty Stable
Common Stock Shares Outstanding973.7 K927.3 K226.4 K
Slightly volatile
Short Term Investments2.4 M2.2 M2.2 M
Pretty Stable
Liabilities And Stockholders Equity16.7 M15.5 M16 M
Slightly volatile
Non Current Liabilities Total1.8 M1.9 M9.9 M
Slightly volatile
Other Stockholder Equity149.3 M142.2 M69.2 M
Slightly volatile
Total Current Assets2.6 M2.7 M8.8 M
Very volatile
Short and Long Term Debt Total1.8 M1.9 M21.4 M
Slightly volatile
Other Liabilities4.6 M4.8 M20.3 M
Slightly volatile
Capital Lease Obligations2.7 M1.6 M5.4 M
Slightly volatile
Net Invested Capital3.9 M4.1 M43.2 M
Slightly volatile
Property Plant And Equipment Gross21.4 M14 M36.6 M
Slightly volatile
Non Current Liabilities Other11.8 M13.3 M14.6 M
Slightly volatile
Short Term Debt362.5 K381.6 K1.4 M
Pretty Stable
Short and Long Term Debt15 M16.9 M18.5 M
Slightly volatile
Current Deferred Revenue180 K202.5 K221 K
Slightly volatile

Scinai Immunotherapeuti Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative4.2 M2.9 M4.2 M
Slightly volatile
Research Development4.6 M6.4 M6.1 M
Slightly volatile
Cost Of Revenue1.2 M1.1 M459 K
Slightly volatile
Depreciation And Amortization2 M1.9 M549.6 K
Slightly volatile
Other Operating Expenses7.3 M10.7 M7.5 M
Slightly volatile
Selling And Marketing Expenses78.6 K82.8 K6.1 M
Very volatile
Interest Income109.2 K115 K408.8 K
Pretty Stable
Reconciled Depreciation1.2 M1.5 M1.6 M
Slightly volatile

Scinai Immunotherapeuti Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Change To Inventory598.8 K664.7 K563.9 K
Slightly volatile
End Period Cash Flow2.3 M2.4 M9 M
Pretty Stable
Begin Period Cash Flow9.2 M5.8 M8.8 M
Slightly volatile
Depreciation2 M1.9 M567.1 K
Slightly volatile
Stock Based Compensation963.5 K784.3 K857.1 K
Slightly volatile
Change To Operating Activities619.6 K351.9 K292.9 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.293.694.033
Slightly volatile
Days Sales Outstanding96.3108118
Slightly volatile
Invested Capital6.2 M6.1 M5.5 M
Very volatile
Average Payables532.3 K711.1 K816.5 K
Pretty Stable
Stock Based Compensation To Revenue0.830.931.0181
Slightly volatile
Capex To Depreciation0.00620.00656.9075
Very volatile
EV To Sales3.433.864.2148
Slightly volatile
Inventory Turnover62.3 K91.5 K95.9 K
Very volatile
Days Of Inventory On Hand0.00780.00410.0041
Pretty Stable
Payables Turnover3.112.960.876
Slightly volatile
Average Inventory0.410.430.4569
Slightly volatile
Research And Ddevelopement To Revenue6.737.578.2594
Slightly volatile
Capex To Revenue0.01460.01640.0179
Slightly volatile
Cash Per Share2.662.8224
Slightly volatile
Days Payables Outstanding1211273.9 K
Pretty Stable
Tangible Asset Value7 M6.8 M6.1 M
Very volatile
Intangibles To Total Assets7.0E-47.0E-40.001
Slightly volatile
Current Ratio1.451.528.451
Slightly volatile
Receivables Turnover2.422.732.9785
Slightly volatile
Graham Number0.00820.00920.01
Slightly volatile
Capex Per Share0.01630.017115.948
Pretty Stable
Average Receivables153.6 K146.3 K194 K
Slightly volatile
Revenue Per Share0.660.730.8018
Slightly volatile
Interest Debt Per Share3.743.9398.7155
Pretty Stable
Debt To Assets0.170.180.8076
Slightly volatile
Operating Cycle114108112
Slightly volatile
Days Of Payables Outstanding1211273.9 K
Pretty Stable
Pretax Profit Margin5.836.567.1601
Slightly volatile
Long Term Debt To Capitalization0.02770.02921.175
Slightly volatile
Total Debt To Capitalization0.190.21.2126
Slightly volatile
Quick Ratio1.451.528.451
Slightly volatile
Cash Ratio0.930.985.5343
Slightly volatile
Days Of Inventory Outstanding0.00780.00410.0041
Pretty Stable
Days Of Sales Outstanding96.3108118
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.221.151.1198
Very volatile
Fixed Asset Turnover0.04760.05360.0585
Slightly volatile
Debt Ratio0.170.180.8076
Slightly volatile
Price Sales Ratio3.293.694.033
Slightly volatile
Asset Turnover0.03910.0440.0481
Slightly volatile
Net Profit Margin5.836.567.1601
Slightly volatile

Scinai Immunotherapeuti Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.8 M3.1 M6.8 M
Slightly volatile
Enterprise Value2.4 M2.5 M7.5 M
Slightly volatile

Scinai Fundamental Market Drivers

Scinai Upcoming Events

15th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Scinai Immunotherapeuti Financial Statements

Investors use fundamental indicators, such as Scinai Immunotherapeuti's revenue or net income, to determine how well the company is positioned to perform in the future. Although Scinai Immunotherapeuti's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue202.5 K180 K
Total Revenue592.2 K1.1 M
Cost Of Revenue1.1 M1.2 M
Stock Based Compensation To Revenue 0.93  0.83 
Research And Ddevelopement To Revenue 7.57  6.73 
Capex To Revenue 0.02  0.01 
Revenue Per Share 0.73  0.66 
Ebit Per Revenue(11.81)(12.41)

Currently Active Assets on Macroaxis

GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft
GOOGAlphabet Inc Class C
GMGeneral Motors
When determining whether Scinai Immunotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scinai Immunotherapeuti's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scinai Immunotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scinai Immunotherapeutics Stock:
How To Invest In Scinai
Details
Is Scinai Stock a good investment?
Details
What is Scinai Immunotherapeuti's Net Worth?
Details
Largest Semiconductors & Semiconductor Equipment Companies
View
Largest Information Technology Companies
View
Check out the analysis of Scinai Immunotherapeuti Correlation against competitors.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Semiconductors & Semiconductor Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scinai Immunotherapeuti. If investors know Scinai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scinai Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.872
Earnings Share
4
Quarterly Revenue Growth
0.361
Return On Assets
(0.40)
Return On Equity
0.1792
The market value of Scinai Immunotherapeutics is measured differently than its book value, which is the value of Scinai that is recorded on the company's balance sheet. Investors also form their own opinion of Scinai Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Scinai Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scinai Immunotherapeuti's market value can be influenced by many factors that don't directly affect Scinai Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between Scinai Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scinai Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scinai Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY